JAZZ Stock Analysis: Buy, Sell, or Hold?
JAZZ - Jazz Pharmaceuticals, Inc.
$225.92
1.26 (0.56%)
▲
5d:
-2.01%
30d:
-5.48%
90d:
+25.08%
BUY
HIGH Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Get Alerted When JAZZ Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: JAZZ shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: JAZZ shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$399.00
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$247.75
8.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: JAZZ is currently trading at $225.92, which is considered oversold relative to its 30-day fair value range of $227.95 to $237.79. From a valuation perspective, the stock is trading at a premium (Forward PE: 8.8) compared to its historical average (8.0). At these levels, the market is pricing in 3.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, JAZZ is in a strong uptrend. The price is currently testing key support at $220.74. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $257.00 (+13.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, JAZZ is in a strong uptrend. The price is currently testing key support at $220.74. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $257.00 (+13.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$227.95 -
$237.79
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
82.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($257.00)
- NEUTRAL: Market pricing in 3.3% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$227.95 -
$237.79
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$9.61
(4.3%)
Support & Resistance Levels
Support Level
$220.74
Resistance Level
$239.62
Current Trend
Strong Uptrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.82
Wall Street Target
$257.00
(+13.8%)
Revenue Growth (YoY)
19.1%
Earnings Growth (YoY)
3.2%
Profit Margin
0.7%
Valuation Premium vs History
+3.3% premium
PE vs Historical
8.8 vs 8.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.3%
(market-implied from PE analysis)
1-Year Target
$233.38
(+3%)
2-Year Target
$241.08
(+7%)
3-Year Target
$249.03
(+10%)
3-Yr Target (if PE normalizes)
(PE: 9→8)
PE COMPRESSION
$225.85
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 87.8%)
$572.64
(+154%)
Base:
(SPY PE: 8.8, Growth: 87.8%)
$231.92
(+3%)
Bear:
(PE: 7.5, Growth: 87.8%)
$197.13
(-13%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (12x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Forward PE: 12.25 | Forward EPS (Implied): $18.44
Bull Case
$272.80
(+21%)
Analyst growth 15.0%, PE expands to 12.9
Base Case
$225.92
(0%)
Market implied 0.0%, PE stable at 12.3
Bear Case
$172.83
(-24%)
Severe decline -15.0%, PE contracts to 11.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 23, 2026 9:41 AM ET
Data refreshes hourly during market hours. Next update: 10:41 AM
Data refreshes hourly during market hours. Next update: 10:41 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JAZZ showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Bruce C Cozadd
SELL
6000 shares
2026-04-01
Patricia Carr
SELL
1287 shares
2026-03-09
Norbert G Riedel
SELL
3415 shares
2026-02-27
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 64 BUY |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 53 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 59 HOLD |
Advanced JAZZ Option Strategies
Professional options setups generated by AI based on today's JAZZ price and gamma walls.
